

a subpoena on Smith, Kline & French which in effect called for every piece of relevant information the company possessed on Eskatrol. Subsequent to that service, SKF, Mission, and Pennwalt withdrew their objections and requests for hearings and by Federal Register notice of August 19, 1971, their drugs joined the other amphetamines in Schedule II.

Mr. Chairman, let me digress for a moment to note a fact important to the purposes of this subcommittee. In our efforts at that time to place the most rigorous controls on the amphetamines we received the support of the American Medical Association. Through its House of Delegates, the AMA expressed approval of the rescheduling and urged "all physicians to limit their use of amphetamines and other stimulant drugs to specific, well-recognized medical indications."

It was early recognized that if our efforts to place the amphetamines in Schedule II succeeded, a new danger to the public might arise. Two drugs - phenmetrazine (Preludin) and methylphenidate (Ritalin) - had been placed in Schedule III by the Congress.